Dr. Yi Ding
Yi Ding, MD, PhD,
System and Core Laboratory Director of Molecular Diagnostics
Associate Director, Geisinger Pathology Residency Program
100 North Academy Avenue
Danville, PA 17822
800-695-6491
Dr. Ding is an associate of Geisinger Medical Laboratories at Danville, Pennsylvania, where she serves as the system and core laboratory director of Molecular Diagnostics. She also serves as the CLIA medicaldDirector of Geisinger Shamokin Area Community Hospital (GSACH), associate professor ofpPathology at Geisinger Commonwealth School of Medicine, and the associate program director of the Geisinger Pathology Residency Program.
Education:
Dr. Ding received her MD from Beijing Medical University in Beijing, China, and her PhD at New York University School of Medicine. She received pathology residency training at New York University Langone Medical Center, New York, New York, and completed fellowships in molecular genetic pathology at New York-Presbyterian Hospital, Weill Cornell Medical College, Cornell University, New York, New York, and in hematopathology at New York University Langone Medical Center, New York, New York.
Certifications:
Dr. Ding is board certified in both anatomic and clinical pathology, molecular genetic pathology, and hematology
Professional Affiliations:
Association for Molecular Pathology (AMP)
College of American Pathologists (CAP)
American Society for Clinical Pathology (ASCP)
United States and Canadian Academy of Pathology (USCAP)
Chinese American Pathologists Association (CAPA)
Research Interests:
Dr. Ding's primary area of interest is in molecular pathology, particularly the application of advanced molecular techniques in oncology, genetic disorders in addition to pharmacogenetics and human ID tests.
Recent Academic Activity
Publications in Peer-Reviewed Journals:
Balu B, Ding Y, Junkins-Hopkins JM. VEXAS syndrome: diagnostic clues for dermatologists. Int J Dermatol. 2023;Online ahead of print:PMID36841896.
Beck DB, Bodian DL, Shah V, Mirshahi UL, Kim J, Ding Y, Magaziner SJ, Strande NT, Cantor A, Haley JS, Cook A, Hill W, Schwartz AL, Grayson PC, Ferrada MA, Kastner DL, Carey DJ, Stewart DR. Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated with VEXAS Syndrome in a Clinical Population. JAMA. 2023;239(4):318-324.
Matsuzawa-Ishimoto Y, Yao X, Koide A, Ueberheide BM, Axelrad JE, Reis BS, Parsa R, Neil JA, Devlin JC, Rudensky E, Dewan MZ, Cammer M, Blumberg RS, Ding Y, Ruggles KV, Mucida D, Koide S and Cadwell K. ?d IEL effector API5 masks genetic susceptibility to Paneth cell death. Nature. 2022;610:547-554.
Ding Y, Zhou Y, Yuan J, Khanna A, Zhang L. Acute leukemias of ambiguous lineage with FLT3-ITD, report of 4 cases. Hematopathology. 2022;7(2):1-10.
Ding Y, Chen G. Molecular testing panel in colorectal cancer. Human Pathology Reports. 2022;28:300632.
Jawad M, Afkhami M, Ding Y, Zhang X, Li P, Young K, Xu ML, Cui W, Zhao Y, Halene S, Al-Kali A, Viswanatha D, Chen D, He R, Zheng G. DNMT3A R882 mutations confer unique clinicopathologic features in MDS including a high risk of AML transformation. Front Oncol. 2022;12:849376.
Ding Y, Smith GH, Deeb K, Schneider T, Campbell A, Zhang L. Revealing Molecular Architecture of FLT3 Internal Tandem Duplication: Development and Clinical Validation of a Web-based Application to Generate Accurate Nomenclature. Int J Lab Hematol. 2022;44(5):918-927.
Ding Y, Campbell A, Zhang X, Fu K, Yuan J. Metachronous and clonally related classic Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Pathology. 2021;53(2):285-288.
Tsongalis GJ, Turkmani MRA, Suriawinata M, Babcock MJ, Mitchell K, Ding Y, Scicchitano L, Tira A, Buckingham L, Atkinson S, Lax A, Aisner AL, Davies KD, Wood HN, O’Neill SS, Levine EA, Sequeira J, Harada S, DeFrank G, Paluri R, Tan BA, Colabella H, Snead C, Cruz-Correa M, Ramirez V, Rojas A, Huang H, Mackinnon AC, Garcia FU, Cavone SM, Elfahal M, Abel G, Vasef MA, Judd A, Linder MW, Alkhateeb K, Skinner WL, Boccia R, Patel K. Comparison of Tissue Molecular Biomarker Testing Turnaround Times and Concordance between Standard of Care and the Biocartis Idylla™ Platform in Colorectal Cancer Patients. Am J Clin Pathol. 2020;154(2):266-276.
Wang W, Ding Y, Campbell A, Handy BC, Medeiros LJ, Lin P. Biclonal presentation of lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia. Pathology. 2019;51(3):340-343.
Xu M, Pokrovskii M, Ding Y, Yi R, Au C, Harrison OJ, Galan C, Belkaid Y, Bonneau R, Littman DR. c-MAF-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont. Nature. 2018;554(7692):373-377.
Ding Y, Miyamoto H, Rothberg PG. Is Tubulocystic Renal Cell Carcinoma Real?: Genomic Analysis Confirms the World Health Organization Classification. J Mol Diagn. 2018;20(1):28-30.
Reyes-Barron C, Burack WR, Rothberg PG, Ding Y. Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update. Crit Rev Oncog. 2017;22(5-6):559-567.
Matsuzawa-Ishimoto Y, Shono Y, Gomez LE, Hubbard-Lucey VM, Cammer M, Neil J, Dewan MZ, Lieberman SR, Jay HV, Lazrak A, Liu C, Ding Y, van den Brink MRM, Cadwell K. Autophagy protein ATG16L1 prevents necroptosis in the intestinal epithelium.. J Exp Med . 2017;214(12):3687-3705.
Other Publications:
Ding Y. BCR-ABL1. Pathology Outlines 2022;March 30.
Ding Y. KRAS. Pathology Outlines 2022;March 21.
Abstracts, Posters, and Other Presentations:
Shah S, Campbell A, Ding Y. It is hard to treat what you can’t see: Hereditary Hemochromatosis workflow improvement at Geisinger. Presentation 112th Annual USCAP Annual Meeting, New Orleans, Louisana, March 11-16, 2023.
Li H, Campbell A, Rovenolt R, Ding Y. Characterization of Homologous Recombination Deficiency-associated Pancreatic Ductal Adenocarcinoma using Oncomine Comprehensive Assay Plus NGS-Based Cancer Panel. Presentation 112th Annual USCAP Annual Meeting, New Orleans, Louisana, March 11-16, 2023.
Kavus H, Campbell A, Scicchitano L, Knock B, Scicchitano M, Kershner J, Ding Y. C282Y, H63D, and S65C HFE gene mutation testing at Geisinger: A five Year Retrospective Study and Workflow Improvement. Presentation 2022 Annual AMP Conference and Expo, Phoenix, Arizona, November 1-5, 2022.
Campbell A, Knock B, Scicchitano M, Chen G, Li H, Ding Y. Performance Evaluation of an Automated Genomic Diagnostic Assay for Myeloproliferative Neoplasms. Presentation 2022 Annual AMP Conference and Expo, Phoenix, Arizona, November 1-5, 2022.
Kavus H, Ding Y, Zhang K. A Rare Case of Systemic Mastocytosis with an Associated Hematological Neoplasm (SM-AHN) and double pathogenic SF3B1 mutations. Presentation College of American Pathologists (CAP) annual meeting , New Orleans, LA, October 2022.
Swid A, Campbell A, Chen G, Ding Y. An autonomous estimation of neoplastic cellularity by molecular methodology shows promising results over the light microscopic assessment. Oral PlatformPresentation Pennsylvania Association of Pathologists (PAP) 2022 Annual Scientific Meeting, Harrisburg, Pennsylvania, April 8-9, 2022.
Jawad M, Afkhami M, Ding Y, Zhang X, Li P, Xu ML, Cui W, Kim YS, Halene S, Viswanatha DS, He R, Chen D, Zheng . DNMT3A R882 mutations confer unique clinicopathologic features in MDS including a high risk of AML transformation. Presentation 111th Annual USCAP Annual Meeting , Los Angeles, California, March 19-24, 2022.
Joseph N, Campbell A, Ding Y. No Bones About It: Disease Monitoring Using Next Generation Sequencing in Peripheral Blood for Patients with Myeloid Neoplasms. Presentation 111th Annual USCAP Annual Meeting , Los Angeles, California, March 19-24, 2022.
Campbell A, Erdman R, Knock B, Scicchitano M, Ding Y. Clinical Validation of the Myeloproliferative Neoplasm Diagnostic Assay on an automated Next Generation Sequencing System. Presentation 2021 Annual AMP Conference & Expo, Philadelphia, Pennsylvania, November 16-20, 2021.
Campbell A, Scicchitano L, Knock B, Rovenolt R, Ding Y. Performance Evaluation of an Economical, Timesaving, Quantitative Molecular Assay for Detection of BCR-ABL1 Transcripts. Presentation 2021 Annual AMP Conference & Expo, Philadelphia, Pennsylvania, November 16-20, 2021.
Lynn TJ, Campbell A, Ding Y. Utility of Next Generation Sequencing in the Workup and Diagnosis of Myeloproliferative neoplasm in the Peripheral Blood: A single institution experience. Presentation ASCP 2021 Annual Conference, Boston, Massachusetts, October 27-29, 2021.
Noor M, Evans AG, Ding Y. T-Cell Lymphoblastic Lymphoma with Unclassified Histiocytic/Dendritic Cell Neoplasm. Presentation Association for Haematopathology (SH-EAHP) 2021 Workshop, Philadelphia, Pennsylvania, November 4-6, 2021.
Lynn TJ, Ding Y, Alvi M, Zelonis MK, Monaco SE. Optimization of Thyroid Samples for Molecular Testing: Lessons learned from indeterminate thyroid fine needle aspirations with suboptimal cytology and molecular testing results. Presentation USCAP 110th Annual Meeting, Virtual and interactive, March 13-18, 2021.
Mohammad M, Smelser D, Ding Y, Carey DJ. Genome wide association of gastroparesis identifies novel disease-associated genetic loci. Presentation USCAP 110th Annual Meeting, Virtual and interactive, March 13-18, 2021.
Lynn TJ, Ding Y, Alvi M, Zelonis MK, Monaco SE. Optimization of Thyroid Samples for Molecular Testing: Lessons learned from indeterminate thyroid fine needle aspirations with suboptimal cytology and molecular testing results. . Abstract and virtual poster United States and Canadian Academy of Pathology, Virtual meeting, March 2021.
Tabish N, Campbell A, Ding Y. Workflow comparison between two NCCN guideline recommended Myeloproliferative Neoplasms screening workup: A single institution’s experience. Presentation 2020 AMP Annual Conference (Virtual and interactive), Vancouver, Canada, Novmeber 16-20, 2020.
Campbell A, Scicchitano L, Knock B, Scicchitano M, Kershner J, Ding Y. Detection of Allelic Dropout in a Mass Array HFE Genotyping Assay. Presentation 2020 AMP Annual Conference (Virtual and interactive), Vancouver, Canada, Novmeber 16-20, 2020.
Sarami I, Scicchitano L, Ding Y. Comparison of oncology biomarker testing turn-around time between standard of care method and a rapid testing platform. Abstract College of American Pathologists 2020 Annual Meeting, Las Vegas, Nevada, October 10-13, 2020.
Sarami I, Smelser DT, Cook AM, Haley JS, Vadakara JJ, Ding Y, Carey DY. A Population-Based Study Identifies Novel Variants for Myelodysplastic Syndrome Associated Genes. Abstract United States and Canadian Academy of Pathology, Los Angeles, California, February 29-March 5, 2020.
Scicchitano L, Brown A, Knock B, Prichard J, Ding Y. Practical Informatics Solutions for Molecular Diagnostics Quality Management.. Abstract Association for Molecular Pathology (AMP) 2019 Annual Meeting, Baltimore, Maryland, November 6-9, 2019.
Katerji H, Katerji R, Campbell A, Rothberg P, Ding Y. Clinical Utilization of Next Generation Sequencing based Clonality Assays for Immunoglobulin Heavy Chain in Evaluating Suspected B-cell Proliferation.. Abstract ASCP 2019 Annual Meeting, Phoenix, Arizona, September 11-13, 2019.
Reyes-Barron C, Ding Y. Detection of ERBB2 Copy Number Variants by Next Generation Sequencing and Comparison to Amplification Detection by Fluorescence in Situ Hybridization, Protein Quantitation Using Fluorescent Nanoparticles and Immunohistochemistry. Abstract USCAP 108th Annual Meeting,, National Harbor, Maryland,, March 16-21, 2019.
Campbell A, Crowe W, Spence J, Spence J, Rothberg P, Ding Y. Identification of FLT3 ITD using Next-Generation Sequencing (NGS): A single institution’s experience. Poster Association for Molecular Pathology (AMP) 2018, San Antonio, Texas, November 1-3, 2018.
Campbell A, Crowe W, Rothberg P, Ding Y.. Clinical Evaluation of the Archer VariantPlex Myeloid Panel for Mutation Profiling in Myeloid Neoplasms. Poster Association for Molecular Pathology (AMP) 2018, San Antonio, Texas, November 1-3, 2018.
Reyes-Barron C, Buscaglia B, Campbell A, Hicks D, Ding Y. Next Generation Sequencing for Quantitative Measurement of Human Epidermal Growth Factor Receptor-2 (HER2) Amplification: a Comparative Study. Poster Association for Molecular Pathology (AMP) 2018, San Antonio, Texas, November 1-3, 2018.
Reyes-Barron C, Campbell A, Rothberg P, Burack R, Ding Y. Next Generation Sequencing-Assays Detect B-Lymphocyte Clonality in Formalin-Fixed Paraffin Embedded Specimens of Classical Hodgkin Lymphoma without Microdissection. Poster Presentation USCAP 107th Annual Meeting, Vancouver, British Columbia, March 17-23, 2018.
Evans A, Ding Y, Laughlin T, Rothberg P, Casulo C, Burack R. IGH sequencing distinguishes multiple EBV+ Mucocutaneous ulcers (MCU) from recurrent malignant DLBCL. Platform Presentation Society of Hematopathology/European Association of Hematopathology Workshop meeting, Chicago, Illinois, September 7-9, 2017.
Crane GM, Rothberg P, Ding Y, Perkins AS, Liesveld JL, Burack R, and Evans AG. MDS/MonoMAC-like syndrome with multiple HPV-driven carcinomas arising in a patient with a novel germline GATA2 variant. Presentation Society of Hematopathology/European Association of Hematopathology Workshop meeting, Chicago, Illinois, September 7-9, 2017.
Ding Y, Crowe W, Spence J, Laughlin T, Spence J, Rothberg P, Burack WR. InDelDuper: a highly sensitive and specific algorithm for FLT3 ITD detection in next-generation. Platform Presentation USCAP 106th Annual Meeting, San Antonio, Texas, March 4-10, 2017.
Ding Y, Rothberg P, Laughlin T, Burack WR, and Evans AG. Multiple independent clonal origins of EBV+ lymphoproliferative disorders revealed by next generation deep sequencing of the immunoglobulin heavy chain (IGH) locus . Platform Presentation USCAP 106th Annual Meeting, San Antonio, Texas, March 4-10, 2017.
Textbooks and Book Chapters
Ding Y, Zhang L. Practical Oncologic Molecular Pathology - Frequently Asked Questions, 1st Edition. Springer, 2021. DOI 10.1007/978-3-030-73227-1. ISBN 978-3-030-73226-4 (hard copy), ISBN 978-3-030-73227-1 (eBook)
Ding Y, Zhang L. The Molecular Pathobiology of Malignant Process and Molecular Diagnostic Testing for Cancer. In Practical Oncologic Molecular Pathology - Frequently Asked Questions, 1st Edition. Ding Y, Zhang L, eds. New York, NY: Springer, 2021: pp. 3-21.
Ding Y, Al-Obaidy KI and Cheng L. Genitourinary Neoplasms. In Practical Oncologic Molecular Pathology - Frequently Asked Questions, 1st Edition. Ding Y, Zhang L, eds. New York, NY: Springer, 2021: pp. 233-244.
Ding Y. Mature B Cell Neoplasms. In Practical Oncologic Molecular Pathology - Frequently Asked Questions, 1st Edition. Ding Y, Zhang L, eds. New York, NY: Springer, 2021: pp. 339-359.
Chen Z, Ding Y, Lin F. Overview of Immunohistochemistry Assessment of Cancer-Related Predictive Biomarkers and Common Genetic Alterations. In Handbook of Practical Immunohistochemistry-Frequently Asked Questions, 3rd ed. Lin F, Prichard J, Liu H, Wilkerson M, eds. New York, New York: Springer, 2022: pp. 131-160.
Zhang M, Ding Y. Lymph node. In Handbook of Practical Immunohistochemistry-Frequently Asked Questions, 3rd ed. Lin F, Prichard J, Liu H, Wilkerson M, eds. New York, New York: Springer, 2022: pp. 751-798.
Yin H, Ding Y, Quinones W, Zelonis M, Snyder D. Application of Fluorescent In Situ Hybridization (FISH) in Surgical and Cytologic Specimens (Solid Tumors, Hematopoietic Tumors, Urine, Bile Duct Brushing, and Bronchoscopy). In Handbook of Practical Immunohistochemistry-Frequently Asked Questions, 3rd ed. Lin F, Prichard J, Liu H, Wilkerson M, eds. New York, New York: Springer, 2022: pp. 975-1006.